Data from Phase IIb AIPAC Trial of Eftilagimod Alpha Shows Promise
Immutep reported positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha and paclitaxel in HER2-negative, HR-positive metastatic breast cancer (MBC).
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news